{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:50:42Z","timestamp":1790041842432,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.clml.2023.09.004","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T05:23:50Z","timestamp":1694755430000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma"],"prefix":"10.1016","volume":"24","author":[{"given":"Monique","family":"Hartley-Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig E.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andreini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Quinn","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5757","authenticated-orcid":false,"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.09.004_bib0001","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: theevolution of current therapy and a glance into future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.09.004_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007087","article-title":"Comprehensive molecular profiling of 718 multiple myelomas reveals significant differences in mutation frequencies between African and European descent cases","volume":"13","author":"Manojlovic","year":"2017","journal-title":"PLoS Genet"},{"key":"10.1016\/j.clml.2023.09.004_bib0003","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/leu.2017.197","article-title":"Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma","volume":"32","author":"Lagan\u00e0","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.09.004_bib0004","unstructured":"Howlader N, Noone AM, Krapcho M, et\u00a0al. SEER Cancer Statistics Review, 1975-2018 [based on November 2020 SEER data submission, posted to the SEER web site, April 2021]. 2021. Available at: https:\/\/seer.cancer.gov\/csr\/1975_2018\/. Accessed: September 7, 2023."},{"key":"10.1016\/j.clml.2023.09.004_bib0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.09.004_bib0006","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1038\/bcj.2017.97","article-title":"Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey","volume":"7","author":"Landgren","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.09.004_bib0007","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-018-0132-1","article-title":"Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry","volume":"8","author":"Baughn","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.09.004_bib0008","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-019-0177-9","article-title":"Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients","volume":"9","author":"Kazandjian","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.09.004_bib0009","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1038\/bcj.2014.91","article-title":"Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study","volume":"5","author":"Greenberg","year":"2015","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.004_bib0010","doi-asserted-by":"crossref","first-page":"7131","DOI":"10.1182\/blood-2022-159189","article-title":"African American race as a risk factor for developing peripheral neuropathy in newly diagnosed patients with multiple myeloma receiving bortezomib induction","volume":"140","author":"Sun","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.004_bib0011","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood-2022-158478","article-title":"Racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T therapy","volume":"140","author":"Peres","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.004_bib0012","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/j.clml.2020.11.013","article-title":"Multiple myeloma in hispanics: incidence, characteristics, survival, results of discovery, and validation using real-world and connect MM registry data","volume":"21","author":"Kaur","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.09.004_bib0013","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-022-00633-5","article-title":"Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study","volume":"12","author":"Dong","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.09.004_bib0014","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1182\/blood.V128.22.4502.4502","article-title":"Practice patterns in newly diagnosed multiple myeloma in the prospective observational Commpass Trial","volume":"128","author":"Necamp","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.004_bib0015","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","article-title":"Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis","volume":"3","author":"Ailawadhi","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.09.004_bib0016","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1080\/10428194.2021.1953013","article-title":"Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study","volume":"62","author":"Al Hadidi","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.09.004_bib0017","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2023.09.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.8161","article-title":"Enrollment of black participants in pivotal clinical trials supporting US Food and Drug Administration approval of chimeric antigen receptor-T cell therapy for hematological malignant neoplasms","volume":"5","author":"Al Hadidi","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.004_bib0019","first-page":"4352","article-title":"FDA analysis of racial demographics in multiple myeloma trials","volume":"130","author":"Bhatnagar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.004_bib0020","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/bloodadvances.2021005482","article-title":"Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials","volume":"6","author":"Kanapuru","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.09.004_bib0021","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.22.00504","article-title":"Are pivotal clinical trials for drugs approved for leukemias and multiple myeloma representative of the population at risk?","volume":"40","author":"Casey","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.09.004_bib0022","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/OP.21.00001","article-title":"Participation of Black Americans in cancer clinical trials: current challenges and proposed solutions","volume":"17","author":"Awidi","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clml.2023.09.004_bib0023","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/107327481602300404","article-title":"Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer","volume":"23","author":"Hamel","year":"2016","journal-title":"Cancer Control"},{"key":"10.1016\/j.clml.2023.09.004_bib0024","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/bloodadvances.2022007679","article-title":"Absolute neutrophil count by Duffy status among healthy Black and African American adults","volume":"7","author":"Merz","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.09.004_bib0025","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1007\/s40615-020-00735-5","article-title":"The effect of discrimination on likelihood of participation in a clinical trial","volume":"7","author":"Devlin","year":"2020","journal-title":"J Racial Ethn Health Disparities"},{"issue":"16 suppl","key":"10.1016\/j.clml.2023.09.004_bib0026","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.2022.40.16_suppl.1014","article-title":"Increasing Black patient participation in metastatic breast cancer clinical trials: the BECOME (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement) project","volume":"40","author":"Walker","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.09.004_bib0027","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jnci\/djaa155","article-title":"When offered to participate\": a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials","volume":"113","author":"Unger","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2023.09.004_bib0028","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.09.004_bib0029","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-020-00347-6","article-title":"Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis","volume":"10","author":"Derman","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.09.004_bib0030","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2023.09.004_bib0031","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2643-3230.BCD-20-0123","article-title":"Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare","volume":"2","author":"Gormley","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.clml.2023.09.004_bib0032","unstructured":"U.S. Food and Drug Administration. Enhancing the diversity of clinical trial populations \u2014 eligibility criteria, enrollment practices, and trial designs guidance for industry. 2020. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial. Accessed: September 7, 2023."},{"key":"10.1016\/j.clml.2023.09.004_bib0033","unstructured":"U.S. Food and Drug Administration. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials; draft guidance for industry; availability. 2022. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-plans-improve-enrollment-participants-underrepresented-racial-and-ethnic-populations. Accessed: September 7, 2023."},{"key":"10.1016\/j.clml.2023.09.004_bib0034","unstructured":"U.S. Food and Drug Administration. Collection of race and ethnicity data in clinical trials. 2016. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/collection-race-and-ethnicity-data-clinical-trials. Accessed: September 7, 2023."},{"key":"10.1016\/j.clml.2023.09.004_bib0035","unstructured":"Food and Drug Administration (FDA). Decentralized clinical trials for drugs, biological products, and devices guidance for industry, investigators, and other stakeholders, draft guidance. 2023. Available at: https:\/\/www.fda.gov\/media\/167696\/download. Accessed: September 7, 2023."},{"key":"10.1016\/j.clml.2023.09.004_bib0036","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1078-0432.CCR-20-3852","article-title":"Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO-Friends of Cancer Research joint research statement","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.09.004_bib0037","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1200\/JCO.22.00754","article-title":"Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers joint research statement","volume":"40","author":"Oyer","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.09.004_bib0038","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1158\/1078-0432.CCR-20-3853","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group","volume":"27","author":"Spira","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.09.004_bib0039","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/jamaoncol.2017.4658","article-title":"Laboratory eligibility criteria as potential barriers to participation by Black men in prostate cancer clinical trials","volume":"4","author":"Vastola","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2023.09.004_bib0040","first-page":"235","article-title":"Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials","volume":"142","author":"Kanapuru","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.004_bib0041","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2023.09.004_bib0042","doi-asserted-by":"crossref","DOI":"10.14694\/EdBook_AM.2013.33.e84","article-title":"The NCI Community Oncology Research Program: what every clinician needs to know","author":"McCaskill-Stevens","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2023.09.004_bib0043","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1200\/OP.22.00378","article-title":"An assessment of the feasibility and utility of an ACCC-ASCO implicit bias training program to enhance racial and ethnic diversity in cancer clinical trials","volume":"19","author":"Barrett","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"12(Suppl)","key":"10.1016\/j.clml.2023.09.004_bib0044","first-page":"PO","article-title":"Abstract PO-276: Lazarex Cancer Foundation (LCF) financial reimbursement programs (FRP) promote equitable access and inclusion among racial\/ethnic minorities in therapeutic cancer clinical trials (TCT)","volume":"29","author":"Dornsife","year":"2020","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.clml.2023.09.004_bib0045","unstructured":"U.S. Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input; guidance for industry, Food and Drug Administration staff, and other stakeholders. 2020. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input. Accessed: September 7, 2023."},{"key":"10.1016\/j.clml.2023.09.004_bib0046","unstructured":"Food and Drug Administration. FDA patient-focused drug development guidance series for enhancing the incorporation of the patient's voice in medical product development and regulatory decision making. 2022. Available at: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical. Accessed: September 7, 2023."},{"key":"10.1016\/j.clml.2023.09.004_bib0047","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1002\/cam4.5552","article-title":"Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study","volume":"12","author":"Eggly","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2023.09.004_bib0048","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1016\/j.pec.2022.09.002","article-title":"Physicians' use of plain language during discussions of prostate cancer clinical trials with patients","volume":"105","author":"Thominet","year":"2022","journal-title":"Patient Educ Couns"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023015513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023015513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:07Z","timestamp":1761871387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023015513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2152265023015513"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}